Completed PHASE2 INTERVENTIONAL 5-arm NCT01620554

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo

Sponsor: Bioprojet

Conditions Excessive Daytime Sleepiness Obstructive Sleep Apnoea

Interventions BF2.649 Placebo

Updated 5 times since 2017 Last updated: Jun 13, 2012 Started: Oct 31, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01620554, this PHASE2 trial focuses on Excessive Daytime Sleepiness and Obstructive Sleep Apnoea and remains completed. Sponsored by Bioprojet, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioprojet

Data source: Bioprojet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grenoble, France